Professor Ninian Lang

Professor (Cardiovascular & Metabolic Health)

telephone: 0141 201 1100
email: Ninian.Lang@glasgow.ac.uk

Biography

Ninian Lang is Professor of Cardiology and Cardio-Oncology. He serves as an Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital and the Beatson West of Scotland Cancer Centre. His clinical and academic work focuses on cardio-oncology and heart failure.

He runs the West of Scotland cardio-oncology service and integrates this clinical practice with an active research programme. His clinical trial and translational research in cardio-oncology relates to vascular and myocardial injury induced by established and novel anti-cancer therapies.

He is a graduate of the University of Edinburgh Medical School (BSc [Neuroscience], 1st class Hons, 1998; MBChB 2001, Annandale Gold Medal in Clinical Surgery). He undertook the majority of his clinical training in cardiology in Lothian. He was awarded the Bristol-Myers Squibb Cardiovascular Prize Fellowship to undertake his PhD research (University of Edinburgh; awarded 2009). He was subsequently appointed as Lecturer in Cardiology at the University of Edinburgh, followed by a fellowship in advanced heart failure and cardiac devices at the Scottish Advanced Heart Failure Service. He was appointed as a consultant cardiologist in 2014 before moving to a substantive position with the University of Glasgow. He is a Fellow of the Royal College of Physicians (Edinburgh) and of the European Society of Cardiology. He is an Associate Editor of the JACC:CardioOncology.

Research interests

Research Theme: Cardiac Diseases

Cardiovascular Oncology

Heart Failure

Research groups

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004

Number of items: 111.

2024

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (Accepted for Publication)

Elyan, B. M.P. , Sullivan, M. K. , Hedley, J., De La Mata, N., Webster, A. C., Venugopal, B., Jones, R. J. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2, 57. (doi: 10.1038/s44276-024-00081-7)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3394) (PMID:39078467) (Early Online Publication)

Shead, K. D., Huethorst, E. , Burton, F., Lang, N. , Myles, R. C. and Smith, G. L. (2024) Human induced pluripotent stem cell derived cardiomyocytes for pre-clinical cardiotoxicity screening. JACC: CardioOncology, (Accepted for Publication)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)

Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, (doi: 10.1002/ehf2.14742) (Early Online Publication)

Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)

Sidik, N. P. et al. (2024) Invasive endotyping in patients with angina and no obstructive coronary artery disease: a randomized controlled trial. Circulation, 149(1), pp. 7-23. (doi: 10.1161/CIRCULATIONAHA.123.064751) (PMID:37795617)

2023

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148(21), pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274) (PMID:37746692) (PMCID:PMC10655910)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Elyan, B. M.P. , Rankin, S., Jones, R., Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

Lees, J. S. , Dobbin, S. J.H. , Elyan, B. M.P. , Gilmour, D. F., Tomlinson, L. P., Lang, N. N. and Mark, P. B. (2023) A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation, 38(7), pp. 1666-1681. (doi: 10.1093/ndt/gfac305) (PMID:36318455) (PMCID:PMC10310520)

Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)

Lees, J. S. , Elyan, B. M.P., Hermann, S. M., Lang, N. N. , Jones, R. J. and Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38(5), pp. 1071-1079. (doi: 10.1093/ndt/gfac011) (PMID:35090037) (PMCID:PMC10157781)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Cohen, J. B., Brown, N. J., Brown, S.-A., Dent, S., van Dorst, D. C.H., Herrmann, S. M., Lang, N. N. , Oudit, G. Y. and Touyz, R. M. (2023) Cancer therapy–related hypertension: a scientific statement from the American Heart Association. Hypertension, 80(3), e46-e57. (doi: 10.1161/HYP.0000000000000224) (PMID:36621810)

Mayne, K. J., Lees, J. S. , Rutherford, E., Thomson, P. C., Traynor, J. P., Dey, V. , Lang, N. N. and Mark, P. B. (2023) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal, 16(3), pp. 512-520. (doi: 10.1093/ckj/sfac248) (PMID:36865003) (PMCID:PMC9972818)

Lim, M. W.S., Setjiadi, D., Dobbin, S. J.H., Lang, N. N. , Delles, C. and Connelly, P. J. (2023) Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review. Blood Pressure Monitoring, 28(1), pp. 24-32. (doi: 10.1097/MBP.0000000000000624) (PMID:36281701) (PMCID:PMC9815820)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

McGettrick, M., Dormand, H., Brewis, M., Johnson, M. K., Lang, N. N. and Church, A. C. (2022) Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease. Frontiers in Cardiovascular Medicine, 9, 1004169. (doi: 10.3389/fcvm.2022.1004169) (PMID:36582741) (PMCID:PMC9793745)

de Wit, S., Glen, C., de Boer, R. A. and Lang, N. N. (2022) Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, 118(8), pp. 3451-3466. (doi: 10.1093/cvr/cvac132) (PMID:36004495) (PMCID:PMC9897696)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Mark, P. B. , Mangion, K., Rankin, A. J. , Rutherford, E., Lang, N. N. , Petrie, M. C. , Stoumpos, S. and Patel, R. K. (2022) Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clinical Kidney Journal, 15(12), pp. 2186-2199. (doi: 10.1093/ckj/sfac146) (PMID:36381379) (PMCID:PMC9664574)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)

Mangion, K. et al. (2022) Multi-system investigation of COVID-19 illness. British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, Manchester, UK, 06-08 June 2022. A122.1-A122. (doi: 10.1136/heartjnl-2022-BCS.157)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Dobbin, S. J.H. , Herrmann, S. M.S., Lang, N. N. , Herrmann, J. and Touyz, R. M. (2022) Hypertension and renal disease before anti-cancer therapies. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 111-122. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00020-9)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Herrmann, S. M.S., Dobbin, S. J.H. , Herrmann, J., Touyz, R. M. and Lang, N. N. (2022) Hypertension and renal disease during anti-cancer therapies. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 185-199. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00029-5)

Lang, N. N. , Dobbin, S. J.H. , Herrmann, S. M.S., Herrmann, J. and Touyz, R. M. (2022) Hypertension and renal failure prevention and management after cancer therapy. In: Herrmann, J. (ed.) Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease. Elsevier: Philadelphia, PA, pp. 286-291. ISBN 9780323681353 (doi: 10.1016/B978-0-323-68135-3.00041-6)

Herrmann, J. et al. (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 43(4), pp. 280-299. (doi: 10.1093/eurheartj/ehab674) (PMID:34904661) (PMCID:PMC8803367)

2021

Lang, N. N. and Touyz, R. M. (2021) Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. Clinical Science, 135(23), pp. 2661-2663. (doi: 10.1042/CS20210986) (PMID:34881389) (PMCID:PMC8672202)

Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Lees, J. S. et al. (2021) Kidney function and cancer risk: an analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 38, 101030. (doi: 10.1016/j.eclinm.2021.101030) (PMID:34505030)

Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)

Noh, R. M., Graveling, A. J., Lang, N. N. , White, A. C., Lee, K. K., Mills, N. L., Newby, D. E., Lang, C. C. and Frier, B. M. (2021) Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: a prospective, randomised, open-label, blinded endpoint, cross-over study. Endocrinology, Diabetes and Metabolism, 4(3), e00258. (doi: 10.1002/edm2.258)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirschner, K. , Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346) (PMCID:PMC8055963)

van Dorst, D. C.H., Dobbin, S. J.H. , Neves, K. B. , Herrmann, J., Herrmann, S. M., Versmissen, J., Mathijssen, R. H.J., Danser, A.H. J. and Lang, N. N. (2021) Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circulation Research, 128(7), pp. 1040-1061. (doi: 10.1161/CIRCRESAHA.121.318051) (PMID:33793337) (PMCID:PMC8011349)

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

McGettrick, M., MacLellan, A., McCaughey, P., Bagot, C., Brewis, M.J., Lang, N.N. , Johnson, M.K. and Church, A.C. (2021) Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 11, e050281. (doi: 10.1136/bmjopen-2021-050281) (PMID:34462282)

2020

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022) (PMID:33303070) (PMCID:PMC7724570)

Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Tzolos, E. et al. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32(5), pp. 292-297. (doi: 10.1016/j.clon.2019.11.008) (PMID:31813662) (PMCID:PMC7139216)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

2019

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Touyz, R. M. and Lang, N. N. (2019) Hypertension and antiangiogenesis: the Janus face of VEGF inhibitors. JACC: CardioOncology, 1(1), pp. 37-40. (doi: 10.1016/j.jaccao.2019.08.010)

Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Lang, N. N. and Walker, N. L. (2018) Adult congenital heart disease and radiation exposure: the malignant price of cardiac care. Circulation, 137(13), pp. 1346-1348. (doi: 10.1161/CIRCULATIONAHA.117.032815) (PMID:29581364)

2017

Noh, R. M., Venkatasubramanian, S., Daga, S., Langrish, J., Mills, N. L., Lang, N. N. , Hoffmann, E., Waterhouse, B., Newby, D. E. and Frier, B. M. (2017) Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus. Open Heart, 4(2), e000647. (doi: 10.1136/openhrt-2017-000647) (PMID:28912956) (PMCID:PMC5588958)

Touyz, R. M. , Lang, N. N. , Herrmann, J., van den Meiracker, A. H. and Danser, A.H. J. (2017) Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension, 70(2), pp. 220-226. (doi: 10.1161/HYPERTENSIONAHA.117.08856) (PMID:28630211) (PMCID:PMC5509510)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

2016

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

Stirrat, C. G., Venkatasubramanian, S., Pawade, T., Mitchell, A. J., Shah, A. S., Lang, N. N. and Newby, D. E. (2016) Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. British Journal of Clinical Pharmacology, 82(4), pp. 974-982. (doi: 10.1111/bcp.13033) (PMID:27275843) (PMCID:PMC5104489)

Pedersen, C. M. et al. (2016) Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury. British Journal of Clinical Pharmacology, 81(6), pp. 1037-1045. (doi: 10.1111/bcp.12882) (PMID:26750458)

Venkatasubramanian, S. et al. (2016) Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. Open Heart, 3(1), e000402. (doi: 10.1136/openhrt-2016-000402) (PMID:27239324) (PMCID:PMC4879341)

2015

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

2014

Lang, N. N. , Badar, A. A., Pettit, S. J., Templeton, S., Connelly, D. T. and Gardner, R. S. (2014) Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. Biomarkers in Medicine, 8(6), pp. 797-806. (doi: 10.2217/BMM.13.159) (PMID:25224936)

Dalzell, J. R., Cannon, J. A., Jackson, C. E., Lang, N. N. and Gardner, R. S. (2014) Emerging biomarkers for heart failure: an update. Biomarkers in Medicine, 8(6), pp. 833-840. (doi: 10.2217/bmm.14.51) (PMID:25224939)

Lang, N. N. , Wong, C. M., Dalzell, J. R., Jansz, S., Leslie, S. J. and Gardner, R. S. (2014) The ease of use and reproducibility of the Alere™ Heart Check System: a comparison of patient and healthcare professional measurement of BNP. Biomarkers in Medicine, 8(6), pp. 791-796. (doi: 10.2217/bmm.14.48) (PMID:25224935)

Liu, D., Fernandez, B. O., Hamilton, A., Lang, N. N. , Gallagher, J. M.C., Newby, D. E., Feelisch, M. and Weller, R. B. (2014) UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. Journal of Investigative Dermatology, 134(7), pp. 1839-1846. (doi: 10.1038/jid.2014.27) (PMID:24445737)

McMinn, J. F., Lang, N. N. , McPhadden, A., Payne, J. R., Petrie, M. C. and Gardner, R. S. (2014) Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine, 8(6), pp. 815-832. (doi: 10.2217/bmm.14.56) (PMID:25224938)

Payne, J. and Lang, N. (2014) Heart failure resistant to standard medical therapy. In: Smith, R., Higgins, M. and Macfie, A. (eds.) Cardiothoracic Critical Care. Series: Oxford specialist handbooks in critical care. Oxford University Press. ISBN 9780199692958 (doi: 10.1093/med/9780199692958.003.0021)

2013

Tsang, H. et al. (2013) Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulmonary Circulation, 3(3), pp. 675-691. (doi: 10.1086/674440) (PMID:24618552) (PMCID:PMC4070793)

Venkatasubramanian, S. et al. (2013) Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. Journal of the American Heart Association, 2(3), e000042. (doi: 10.1161/JAHA.113.000042) (PMID:23770971) (PMCID:PMC3698759)

Japp, A. G. et al. (2013) Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. Journal of the American Heart Association, 2(1), e006007. (doi: 10.1161/JAHA.112.006007) (PMID:23525448) (PMCID:PMC3603266)

Venkatasubramanian, S., Griffiths, M. E., McLean, S. G., Miller, M. R., Luo, R., Lang, N. N. and Newby, D. E. (2013) Vascular effects of Urocortins 2 and 3 in healthy volunteers. Journal of the American Heart Association, 2(1), e004267. (PMID:23525432) (PMCID:PMC3603262)

Lang, N.N. (2013) Cardiology Symposium 2012 Report held on 15 November at the Royal College of Physicians of Edinburgh. Journal of the Royal College of Physicians of Edinburgh, 43(2), pp. 159-160. (doi: 10.4997/JRCPE.2013.214)

Lang, N.N. and Connelly, D.T. (2013) Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. Journal of the Royal College of Physicians of Edinburgh, 43(2), pp. 151-158. (doi: 10.4997/JRCPE.2013.213)

2012

Alam, S. R. et al. (2012) Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circulation: Cardiovascular Imaging, 5(5), pp. 559-565. (doi: 10.1161/CIRCIMAGING.112.974907) (PMID:22875883)

Lang, N.N. and Newby, D.E. (2012) Cardiac compression causing fatal acute ST-segment elevation myocardial infarction. QJM: An International Journal of Medicine, 105(9), pp. 883-885. (doi: 10.1093/qjmed/hcr131) (PMID:21804101)

Richards, J. M.J. et al. (2012) In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circulation: Cardiovascular Imaging, 5(4), pp. 509-517. (doi: 10.1161/CIRCIMAGING.112.972596) (PMID:22787016)

Cruden, N. L.M., Lang, N. N. , MacGillivray, T. J., Uren, N. G., Fox, K. A.A. and Newby, D. E. (2012) Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. Heart and Vessels, 27(2), pp. 179-185. (doi: 10.1007/s00380-011-0124-6) (PMID:21394642)

2011

Lang, N. N. , Guðmundsdóttir, I. J. and Newby, D. E. (2011) Vascular PAR-1: activity and antagonism. Cardiovascular Therapeutics, 29(6), pp. 349-361. (doi: 10.1111/j.1755-5922.2010.00140.x) (PMID:20528879)

2010

Lang, N. and Fox, K. (2010) Current drug therapies used in the secondary prevention of MI. Prescriber, 21(19), pp. 22-45. (doi: 10.1002/psb.675)

Venkatasubramanian, S., Newby, D. E. and Lang, N. N. (2010) Urocortins in heart failure. Biochemical Pharmacology, 80(3), pp. 289-296. (doi: 10.1016/j.bcp.2010.03.032) (PMID:20363214)

2009

Mills, N.L., Tura, O., Padfield, G.J., Millar, C., Lang, N.N. , Stirling, D., Ludlam, C., Turner, M.L., Barclay, G.R. and Newby, D.E. (2009) Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart, 95(24), pp. 2003-2008. (doi: 10.1136/hrt.2008.163162) (PMID:19482845)

2008

Lang, N. N. , Cruden, N. L., Tse, G. H., Bloomfield, P., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2008) Vascular B1 kinin receptors in patients with congestive heart failure. Journal of Cardiovascular Pharmacology, 52(5), pp. 438-444. (doi: 10.1097/FJC.0b013e31818c66cb) (PMID:19033823)

Lang, N. N. , Guðmundsdóttir, I. J., Boon, N. N., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2008) Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers. Journal of the American College of Cardiology, 52(1), pp. 33-39. (doi: 10.1016/j.jacc.2008.04.003) (PMID:18582632)

Guðmundsdóttir, I. J., Lang, N. N. , Boon, N. A., Ludlam, C. A., Webb, D. J., Fox, K. A. and Newby, D. E. (2008) Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. Journal of the American College of Cardiology, 51(18), pp. 1749-1756. (doi: 10.1016/j.jacc.2007.12.047) (PMID:18452780)

Lang, N. and Fox, K. (2008) Current drug therapies for the secondary prevention of MI. Prescriber, 19(1), pp. 14-25. (doi: 10.1002/psb.173)

Lang, N.N. , Myles, R.C., Burton, F.L., Hall, D.P., Chin, Y.Z., Boon, N.A. and Newby, D.E. (2008) The vascular effects of rotigaptide in vivo in man. Biochemical Pharmacology, 76(10), pp. 1194-1200. (doi: 10.1016/j.bcp.2008.08.022)

Lang, N. N. and Newby, D. E. (2008) Investigation of patients with suspected chronic heart failure. In: Kearney, M. (ed.) Chronic Heart Failure. Series: Oxford cardiology library. Oxford University Press: Oxford, pp. 23-34. ISBN 9780199542338 (doi: 10.1093/med/9780199542338.003.0003)

2007

Lang, N. N. , Luksha, L., Newby, D. E. and Kublickiene, K. (2007) Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. American Journal of Physiology: Heart and Circulatory Physiology, 292(2), H1026-H1032. (doi: 10.1152/ajpheart.00797.2006) (PMID:17085540)

Lang, N. N. and Newby, D. E. (2007) Emerging thrombotic effects of drug eluting stents. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(2), pp. 261-262. (doi: 10.1161/01.ATV.0000255308.41576.ae) (PMID:17229968)

2005

Lang, N. and Fox, K. (2005) Current drug therapies for the secondary prevention of MI. Prescriber, 16(12), pp. 33-44.

2004

Lang, N. , Davie, R., Whitworth, C., Winney, R. and Hughes, J. (2004) Fatal calcific uraemic arteriolopathy (CUA): a case report and review of the literature. Scottish Medical Journal, 49(3), pp. 108-111. (doi: 10.1177/003693300404900313) (PMID:15462229)

This list was generated on Thu Oct 24 01:38:58 2024 BST.

Jump to: Articles | Book Sections | Conference or Workshop Item